GlobalData on MSN4d
Kezar Life Sciences discontinues lupus nephritis programme after fatalities
Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...
Lupus Foundation of America29d
UCB and Biogen Announce Positive Phase III Clinical Trial Results for Dapirolizumab Pegol for Treatment of Systemic Lupus Erythematosus
UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...
Lupus Foundation of America14d
Review of Neuropsychiatric Lupus Diagnosis and Management
Neuropsychiatric systemic lupus erythematosus ... understanding and managing NPSLE, further research and clinical studies for ...
Pharmabiz5d
Cullinan Therapeutics gets US FDA clearance to proceed phase 1 trial of CLN-978 in patients with moderate to severe systemic lupus erythematosus
Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash
Investing in Cabaletta Bio for potential high returns on innovative CAR-T therapies despite volatility and risk. Click here ...
Monthly Prescribing Reference29d
Dapirolizumab Pegol Looks Promising for Systemic Lupus Erythematosus
The trial met its primary composite endpoint demonstrating significant clinical improvement ... in patients with moderate to severe systemic lupus erythematosus (SLE). Dapirolizumab pegol is ...
Investing6d
FDA approves Cullinan's lupus drug for Phase 1 trials
to proceed with Phase 1 clinical trials in the United States for its drug candidate CLN-978, targeting systemic lupus erythematosus (SLE), a chronic autoimmune disease. The clearance allows the ...
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral ...
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Completes Transition to Immune-Mediated Disease Focused CompanyHighlights Additional Data from Phase 1b Primary Membranous ...
Investing6d
FDA approves Cullinan's lupus drug for Phase 1 trials
to proceed with Phase 1 clinical trials in the United States for its drug candidate CLN-978, targeting systemic lupus erythematosus (SLE), a chronic autoimmune disease. The clearance allows the ...